

Production of a single batch of 15 billion hiPS cells within a 10L bioreactor with an exponential amplification factor of 276-fold in 6.59 Days.


Elisa Luquet<sup>1</sup>, Justine Pletenka<sup>1</sup>, Maëlle De Marco<sup>1</sup>, Emilie Jamet<sup>1</sup>, Hélène Wurtz<sup>1</sup>, Philippe Cohen<sup>1,2</sup>, Fabien Moncaubeig<sup>1</sup>, Michael Lanero Fidalgo<sup>1</sup>, Kévin Alessandri<sup>1</sup>, and Maxime Feyeux<sup>1</sup>

<sup>1</sup> TreeFrog Therapeutics, 30 avenue Gustave Eiffel, Bât A, 33600 Pessac - France  
<sup>2</sup> Imagine Institute, iPS platform, 24 boulevard de Montparnasse, 75015 Paris - France



Introduction

So far, only a few teams have publicly shared results showing the successful cultivation of pluripotent stem cells in large-scale bioreactors. Here using new technology based on high-speed cell encapsulation microfluidics, we report a 276-fold amplification of hiPSCs over 6.59 days in a 10L bioreactor with best-in-class cell viability and pluripotency.


High-throughput cell encapsulation of 50M hiPS cells



276-fold amplification of hiPSCs in a 10L bioreactor, with striking reproducibility




C-Stem™ enables ultra-fast scale-up to 10L bioreactor with exponential hiPSC amplification




The same exponential amplification profile was observed across a broad range of bioreactor scales, without optimization, demonstrating that **C-Stem™** constitutes a highly scalable and reproducible technology for hiPSC mass-production.

The iPS cell line IMAGINi005 previously characterized<sup>1</sup> at Imagine Institute iPS platform was used.

Exponential hiPS cell expansion in bioreactor with conservation of stemness



FACS Plots of Batch #1



Conclusion

Here, we report the unprecedented 276-fold amplification of hiPS cells in a 10L bioreactor in 6.59 days, with outstanding reproducibility. Notably, the generated cells exhibit an exceptional quality in terms of stemness and viability. The success of the first runs in a 10L bioreactor, without any optimization, demonstrates the genuine scalability of C-Stem™.

Perspectives

**C-Stem™** also enables the differentiation of hiPSCs in bioreactors into functional microtissues ready for transplantation. **C-Stem™** technology is currently applied to several iPS-derived cell therapy programs, including the production of dopaminergic neurospheres to treat Parkinson's disease. The next step will be to reach GMP compliance in early 2022, with the view of addressing a broad range of scales, from 500mL to 1000L, for applications demanding a large number of cells, such as stem cell banking and therapies for cardiac or hepatic diseases.

